Peer Exchange

Clinical pathways considerations and key treatment strategies for hepatocellular carcinoma (HCC) are discussed by a panel of medical experts.

A panel of medical experts hold a discussion surrounding updates in metastatic colorectal cancer.

Hilary Baldwin, MD, Arash Mostaghimi, MD, Steven Feldman, MD, PhD, and Casey Butrus, PharmD, discuss updates in acne therapy and multidisciplinary care for patients.

A panel of experts explore a novel class of medications for patients with metastatic breast cancer, the oral selective estrogen receptor degrader (SERDs).

A panel of medical experts will gather to discuss current and unmet needs in the treatment landscape of schizophrenia.

A panel of medical experts explore CDK 4/6 inhibitors for patients diagnosed with high-risk early breast cancer.

A panel of experts describe the burden of the HIV epidemic including its impacts on patients and payers, review the latest evidence and treatment guidelines informing decision-making in HIV, and discuss unmet needs and future directions in the treatment of HIV.

A panel of medical experts discuss the significance of RSV vaccination.

Ryan Haumschild, PharmD, MS, MBA leads a panel of medical experts in a discussion surrounding the potential role of BTK inhibitors in the treatment of multiple sclerosis.

Medical experts explore the use of bispecifics in the relapsed / refractory myeloma treatment landscape.

A panel of medical experts discuss the current treatment landscape surrounding atopic dermatitis.

A panel of medical experts provide insights on the treatment landscape of Multidrug-Resistant HIV.

A panel of medical experts describe the treatment landscape of Geographic Atrophy.

Experts discuss the disease burden and treatment landscape for age-related macular degeneration (AMD), and diabetic macular edema (DME).

A panel of medical experts provide insights to the treatment landscape surrounding multiple myeloma (MM).

A panel of experts provide an overview of the disease burden associated with leukemia and lymphoma, discuss the current treatment landscape of BTK inhibitors, and offer payer considerations in treatment management.

Medical experts discuss optimal treatment strategies and current standards of care surrounding therapy for patients with COPD.

A panel of experts describe the clinical burden of myelodysplastic syndromes (MDS), discuss treatment paradigms and standard of care therapies, and explore unmet needs and future directions in the treatment of MDS.

A panel of experts explore the clinical and economic burden of vitiligo, review treatment paradigms and standard of care therapies, and discuss unmet needs and future directions for treatment of vitiligo.

An expert panel discusses chronic kidney disease (CKD), its impact on cardiovascular disease (CV), and the methods of treatment used on the patient populations.

A panel of experts explore the updated heart failure guidelines and the impact on current treatment landscape for patients, with a focus on evidence-based medicine, payer strategies, and collaborative care management.

A panel of experts provide an overview of the burden of common health concerns in women’s reproductive years, review currently available treatment options, and discuss a personalized treatment approach for women’s reproductive health. Ryan Haumschild, PharmD, MBA, MS, discusses implications of the Affordable Care Act (ACA) to women’s reproductive health, along with methods to ensure timely access to appropriate therapy.

A panel of expert discuss interstitial lung disease (ILD) in depth, from definition to the best possible therapy options for treatment.

A panel of experts explore the patient journey and unmet needs of patients with treatment resistant depression (TRD), outline treatment strategies for TRD outside of oral antidepressants/antipsychotics and explore strategies to support access to these alternative therapies through improved billing/coding strategies.

A panel of clinicians and managed care decision makers describe how to best refer to real-world evidence when making treatment decisions for patients with multiple myeloma.

Payer and clinician insight regarding the integration of comprehensive genomic profiling into routine clinical practice to help oncologists make more informed treatment decisions for patients with cancer.

Expert panelists provide an overview of the burden of MDS, review currently available treatment options, and explore the clinical and payer considerations of oral treatments.

Jim Kenney, RPh, MBA; Kevin U. Stephens, Sr, JD, MD; Philip Niles, MD, MBA; and Nicholas G. Anderson, MD, review the clinical and economic burden of wet AMD and diabetic macular edema (DME), share currently available treatment options, and discuss considerations for emerging ophthalmic therapies.